Drug interactions
Ipilimumab + Lisocabtagene maraleucel
Severity: Moderate
Ipilimumab and Lisocabtagene maraleucel: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ipilimumab enhances T-cell activation, and lisocabtagene maraleucel is a CAR-T product with risks of cytokine release syndrome and neurologic toxicity. Together they may heighten immune-mediated adverse effects, with limited clinical data to guide use.
What this interaction means in plain words
Ipilimumab and Lisocabtagene maraleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ipilimumab belongs to Oncology; Lisocabtagene maraleucel belongs to Oncology.
Why it happens
Additive immune modulation; checkpoint blockade may augment CAR-T activity and toxicity, a largely theoretical interaction.
What to do
Avoid concurrent use around CAR-T infusion unless clearly necessary. If used, monitor for cytokine release syndrome, neurotoxicity, immune-related adverse events and infection.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ipilimumab and Lisocabtagene maraleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ipilimumab
Other interactions of Lisocabtagene maraleucel
Frequently asked questions
Can I take Ipilimumab with Lisocabtagene maraleucel?
MediHelp rates the interaction as moderate. Ipilimumab and Lisocabtagene maraleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ipilimumab enhances T-cell activation, and lisocabtagene maraleucel is a CAR-T product with risks of cytokine release syndrome and neurologic toxicity. Together they may heighten immune-mediated adverse effects, with limited clinical data to guide use.
How serious is the interaction between Ipilimumab and Lisocabtagene maraleucel?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use around CAR-T infusion unless clearly necessary. If used, monitor for cytokine release syndrome, neurotoxicity, immune-related adverse events and infection.
What other medicines interact with Ipilimumab?
MediHelp also lists interactions of Ipilimumab with, for example, Etrasimod, Vemurafenib, Ciltacabtagene autoleucel. The full list is on the Ipilimumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
